Purpose <p>The objective of this research was to explore the application of controlled ice nucleation (CN) technology to enhance the critical quality attributes (CQAs) and manufacturing efficiency of freeze-dried monoclonal antibody (mAb) drug products. The study aimed to address challenges associated with conventional freeze-drying process, such as low supercooling temperatures and inhomogeneous ice nucleation temperatures, and to evaluate whether CN could improve product quality, and the overall efficiency of the lyophilization process.</p> Methods <p>Various mAb drug products were manufactured using three different lyophilization methods during the freezing step, including conventional, annealing, and CN. The CQAs of the drug products were assessed, including residual moisture content, reconstitution time, product appearance, microscopic morphology, specific surface area, protein purity, charge variance, and sub-visible particulates. Comparative analyses were conducted to evaluate the impact of the CN on product quality and process efficiency.</p> Results <p>CN demonstrated significant improvements in product appearance, uniformity, reconstitution properties, and stability. It notably reduced the primary drying time, enhancing the overall efficiency of the freeze-drying process. Furthermore, the CN method produced lyophilized drug products with consistent cake appearance, improved quality, and enhanced stability, ensuring therapeutic efficacy and patient safety.</p> Conclusions <p>CN technology represents a major advancement in pharmaceutical manufacturing. The implementation of CN has the potential to improve the CQAs of drug products, optimize the lyophilization process, reduce operational costs, and increase production throughput. These findings underscore the importance of adopting innovative technologies like CN to meet the growing demand for high-quality and efficient biopharmaceutical production.</p>